HRP20140195T1 - Supstituirani derivati triazolopiridazina - Google Patents

Supstituirani derivati triazolopiridazina Download PDF

Info

Publication number
HRP20140195T1
HRP20140195T1 HRP20140195AT HRP20140195T HRP20140195T1 HR P20140195 T1 HRP20140195 T1 HR P20140195T1 HR P20140195A T HRP20140195A T HR P20140195AT HR P20140195 T HRP20140195 T HR P20140195T HR P20140195 T1 HRP20140195 T1 HR P20140195T1
Authority
HR
Croatia
Prior art keywords
substance
composition
deuterium
pharmaceutically acceptable
disease
Prior art date
Application number
HRP20140195AT
Other languages
English (en)
Croatian (hr)
Inventor
Scott Harbeson
Original Assignee
Concert Pharmaceuticals Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Concert Pharmaceuticals Inc. filed Critical Concert Pharmaceuticals Inc.
Publication of HRP20140195T1 publication Critical patent/HRP20140195T1/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/002—Heterocyclic compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HRP20140195AT 2008-08-29 2009-08-28 Supstituirani derivati triazolopiridazina HRP20140195T1 (hr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US9329308P 2008-08-29 2008-08-29
PCT/US2009/055427 WO2010025407A1 (en) 2008-08-29 2009-08-28 Substituted triazolo-pyridazine derivatives

Publications (1)

Publication Number Publication Date
HRP20140195T1 true HRP20140195T1 (hr) 2014-04-11

Family

ID=41721962

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20140195AT HRP20140195T1 (hr) 2008-08-29 2009-08-28 Supstituirani derivati triazolopiridazina

Country Status (17)

Country Link
US (4) US8003646B2 (https=)
EP (2) EP2328414B1 (https=)
JP (3) JP5183808B2 (https=)
KR (1) KR20110063479A (https=)
CN (2) CN104098578A (https=)
AU (1) AU2009285533B2 (https=)
BR (1) BRPI0912928A2 (https=)
CA (1) CA2735549A1 (https=)
DK (1) DK2328414T3 (https=)
EA (1) EA020071B1 (https=)
ES (1) ES2451542T3 (https=)
HR (1) HRP20140195T1 (https=)
MX (1) MX2011002278A (https=)
PL (1) PL2328414T3 (https=)
PT (1) PT2328414E (https=)
WO (1) WO2010025407A1 (https=)
ZA (1) ZA201102123B (https=)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104098578A (zh) * 2008-08-29 2014-10-15 康瑟特制药公司 取代的三唑并哒嗪衍生物
WO2010037194A1 (pt) 2008-10-03 2010-04-08 Instituto Alberto Luiz De Coimbra De Pós Graduação E Pesquisa De Engenharia - Coppe/Ufrj Dispositivo para remoção de fragmentos metálicos e elementos metálicos do interior de canáis radiculares de dentes e processo para remoção dos mesmos
JP2012531419A (ja) 2009-06-23 2012-12-10 コンサート ファーマシューティカルズ インコーポレイテッド Ｇａｂａ−ａ受容体修飾物質としての重水素修飾されたトリアゾロピリダジン誘導体
JP2014530870A (ja) * 2011-10-20 2014-11-20 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニーＧｌａｘｏＳｍｉｔｈＫｌｉｎｅ ＬＬＣ サーチュイン調節因子としての置換された二環式アザ複素環およびアナログ
JP6073343B2 (ja) 2011-10-20 2017-02-01 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニーＧｌａｘｏＳｍｉｔｈＫｌｉｎｅ ＬＬＣ サーチュイン調節因子としての置換された二環式アザ複素環およびアナログ
HK1201270A1 (en) 2012-01-11 2015-08-28 Bayer Intellectual Property Gmbh Tetrazol-5-yl- and triazol-5-yl-aryl compounds and use thereof as herbicides
US20150099753A1 (en) * 2012-05-11 2015-04-09 Concert Pharmaceuticals Inc. Form 5 polymorph of 7-(tert-butyl-d9)-3-(2,5-difluorophenyl)-6-((1-methyl-1h-1,2,4-triazol-5-yl)methoxy)-[1,2,4]triazolo[4,3-b]pyridazine
WO2013170242A1 (en) * 2012-05-11 2013-11-14 Concert Pharmaceuticals, Inc. Form 2 polymorph of 7-(tert-butyl-d9)-3-(2,5-difluorophenyl)-6-((1-methyl-1h-1,2,4-triazol-5-yl)methoxy)-[1,2,4]triazolo[4,3-b]pyridazine
US20150158870A1 (en) * 2012-05-11 2015-06-11 Concert Pharmaceuticals Inc. Polymorphs of 7-(tert-butyl-d9)-3-(2,5-difluorophenyl)-6-((1-methyl-1h-1,2,4-triazol-5-yl)methoxy)-[1,2,4]triazolo[4,3-b]pyridazine
WO2015052173A1 (en) 2013-10-10 2015-04-16 Basf Se Tetrazole and triazole compounds and their use as herbicides
WO2015052178A1 (en) 2013-10-10 2015-04-16 Basf Se 1,2,5-oxadiazole compounds and their use as herbicides
WO2015095549A1 (en) * 2013-12-18 2015-06-25 Concert Pharmaceuticals, Inc. Dosage regimen for gabaa receptor subtype selective drug
KR20160117596A (ko) 2014-02-07 2016-10-10 오스펙스 파마슈티칼스, 인코포레이티드 신규 제약 제제
CN104474549A (zh) * 2014-11-24 2015-04-01 王寿世 异丙酚和gabaa受体拮抗剂在制备麻醉药物中的用途
CN104353078B (zh) * 2014-11-24 2017-10-24 王寿世 一种麻醉用药物组合物
US10026332B1 (en) 2017-04-10 2018-07-17 Jasmine Gupta Method to deliver contextual educational information utilizing smart wearables
CA3132810A1 (en) * 2019-03-18 2020-09-24 Neurocycle Therapeutics, Inc. Use of gabaa receptor modulators for treatment of fybromyalgia
EP4511025A4 (en) * 2022-04-20 2026-04-15 Engrail Therapeutics Inc GABAa receptor modulator salts, particles, and their uses

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9321162D0 (en) 1993-10-13 1993-12-01 Boots Co Plc Therapeutic agents
US6221335B1 (en) * 1994-03-25 2001-04-24 Isotechnika, Inc. Method of using deuterated calcium channel blockers
ES2293638T3 (es) 1994-03-25 2008-03-16 Isotechnika, Inc. Mejora de la eficacia de farmacos por deuteracion.
KR20000029548A (ko) * 1996-07-25 2000-05-25 더블유. 지. 콜 가바수용체에대한리간드로서의치환된트리아졸로-피리다진유도체
HUP0100575A3 (en) * 1998-01-21 2003-03-28 Merck Sharp & Dohme Ltd Hoddes Triazolo-pyridazine derivatives as ligands for gaba receptors
US6440710B1 (en) * 1998-12-10 2002-08-27 The Scripps Research Institute Antibody-catalyzed deuteration, tritiation, dedeuteration or detritiation of carbonyl compounds
ATE284403T1 (de) * 1999-01-27 2004-12-15 Merck Sharp & Dohme Triazolopyridazinderivate als liganden für gaba- rezeptoren
PT1104760E (pt) * 1999-12-03 2003-06-30 Pfizer Prod Inc Compostos de sulfamoil-heteroarilpirazole como agentes analgesicos e anti-inflamatorios
US20020165217A1 (en) * 2001-05-01 2002-11-07 Pfizer Inc. Combination treatment for anxiety and depression
TW200413273A (en) * 2002-11-15 2004-08-01 Wako Pure Chem Ind Ltd Heavy hydrogenation method of heterocyclic rings
WO2004048980A1 (en) * 2002-11-28 2004-06-10 Neurosearch A/S Method for screening for compounds as potential sedatives or anxiolytics
WO2006061428A2 (en) 2004-12-10 2006-06-15 Universität Zürich Gaba-a alpha 2 and alpha 3 receptor agonists for treating neuropathic, inflammatory and migraine associated pain
EP1934201A1 (en) * 2005-10-06 2008-06-25 Auspex Pharmaceuticals Inc. Deuterated inhibitors of gastric h+, k+-atpase with enhanced therapeutic properties
US7750168B2 (en) * 2006-02-10 2010-07-06 Sigma-Aldrich Co. Stabilized deuteroborane-tetrahydrofuran complex
JO2630B1 (en) 2006-04-13 2012-06-17 نوفارتيس ايه جي Organic compounds
JP2010501572A (ja) * 2006-08-22 2010-01-21 コンサート ファーマシューティカルズ インコーポレイテッド ４−アミノキナゾリン誘導体およびその使用方法
US20080103122A1 (en) * 2006-09-05 2008-05-01 Schering Corporation Pharmaceutical combinations for lipid management and in the treatment of atherosclerosis and hepatic steatosis
AU2008232425A1 (en) * 2007-04-02 2008-10-09 Auspex Pharmaceuticals, Inc. Substituted pyrimidines
CN104098578A (zh) * 2008-08-29 2014-10-15 康瑟特制药公司 取代的三唑并哒嗪衍生物

Also Published As

Publication number Publication date
BRPI0912928A2 (pt) 2015-08-04
DK2328414T3 (en) 2014-03-10
JP5183808B2 (ja) 2013-04-17
EA201100409A1 (ru) 2011-10-31
US20100056529A1 (en) 2010-03-04
JP2012501346A (ja) 2012-01-19
ZA201102123B (en) 2011-12-28
CN102176826B (zh) 2014-08-20
US8921366B2 (en) 2014-12-30
JP2014058518A (ja) 2014-04-03
AU2009285533A2 (en) 2011-04-21
US20130225590A1 (en) 2013-08-29
EP2328414A4 (en) 2011-11-16
US8399467B2 (en) 2013-03-19
US20120004236A1 (en) 2012-01-05
KR20110063479A (ko) 2011-06-10
PL2328414T3 (pl) 2014-05-30
CA2735549A1 (en) 2010-03-04
JP5373982B2 (ja) 2013-12-18
US8003646B2 (en) 2011-08-23
PT2328414E (pt) 2014-03-17
ES2451542T3 (es) 2014-03-27
EP2716158A1 (en) 2014-04-09
WO2010025407A1 (en) 2010-03-04
EA020071B1 (ru) 2014-08-29
AU2009285533A1 (en) 2010-03-04
AU2009285533B2 (en) 2014-02-13
MX2011002278A (es) 2011-04-14
EP2328414B1 (en) 2013-12-11
EP2328414A1 (en) 2011-06-08
CN102176826A (zh) 2011-09-07
CN104098578A (zh) 2014-10-15
JP2013100322A (ja) 2013-05-23
US20150111895A1 (en) 2015-04-23

Similar Documents

Publication Publication Date Title
HRP20140195T1 (hr) Supstituirani derivati triazolopiridazina
HRP20110289T1 (hr) Makrociklički inhibitori virusa hepatitisa c
WO2019079607A9 (en) Methods of using ehmt2 inhibitors in treating or preventing blood disorders
HRP20241540T1 (hr) Pirolotriazinski spojevi koji djeluju kao inhibitor mnk
ES2630115T3 (es) Derivados de 5-fluoro-n-(piridin-2-il)piridin-2-amina con sulfoximina sustituida y su uso como inhibidores de quinasa cdk9
HRP20160641T1 (hr) Fuzionirani triciklički spojevi kao inhibitori raf kinaze
HRP20160030T1 (hr) Derivati 6,7-dihidro-pirazolo[1,5-a]pirazin-4-ilamina koji su korisni kao inhibitori beta-sekretaze (bace)
ME02672B (me) Fenil-3-aza-bicikl0[3.1.0]heks-3-il-metanoni i njihova primena kao medikament
MX367292B (es) Ligandos para formacion de imagen de inervacion cardiaca.
JP2019529444A (ja) アルキル置換複素環化合物、そのための調製方法およびその医学的用途
AR063351A1 (es) DERIVADOS DE PURINA Y DE PIRIMIDINAS CONDENSADAS, COMPOSICION Y SU USO EN LA PREPARACIoN DE UN MEDICAMENTO PARA INHIBIR EL HSP90 EN UNA CELULA.
ME02490B (me) Hemijska jedinjenja
ME02321B (me) Antivirusna jedinjenja
HRP20130942T1 (hr) Aminodiazepini kao modulatori toll-u sliäśnih receptora
HRP20211973T1 (hr) Kinazolini kao inhibitori ionskih kalijskih kanala
HRP20170955T1 (hr) Derivati kinolin-8-sulfonamida s antikancerogenim djelovanjem
MA30464B1 (fr) Nouvelle forme cristalline vi de l'agomelatine, son procede de preparation et les compositions pharmaceutiques qui la contiennent
WO2017139404A1 (en) Methods of treating cancer
BR122012009489B8 (pt) processo para produzir 2-etóxi-1-{[2’-(5-oxo-4,5-diidro-1,2,4-oxadiazol-3-il)bifenil-4-il]metil}-1h-benzimidazol-7-carboxilato de (5-metil-2-oxo-1,3-dioxol-4-il)metila ou um sal do mesmo, composição farmacéutica, e, uso
AU2012335981C1 (en) Tricyclic amino containing compounds for treatment or prevention of symptoms associated with endocrine dysfunction
MX2009011812A (es) Aminopirimidinas utiles como inhibidores de cinasa.
HRP20140409T1 (hr) Derivat imidazola sa strukturom prolinskog prstena
HRP20171053T1 (hr) Derivati oksokinazolinil-butanamida
TN2009000483A1 (fr) Derives de 7-alkynyl-1-8-naphthyridones, leur preparation et leur application en therapeutique
RU2020123899A (ru) Новые соединения, ингибирующие mtor